Etzer Darout
Stock Analyst at Guggenheim
(3.32)
# 1,198
Out of 4,983 analysts
119
Total ratings
43.21%
Success rate
5.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Initiates: Equal-Weight | $40 | $39.14 | +2.20% | 4 | Sep 17, 2025 | |
| CTMX CytomX Therapeutics | Assumes: Overweight | $3.5 | $1.96 | +78.57% | 11 | Sep 17, 2025 | |
| TERN Terns Pharmaceuticals | Initiates: Overweight | $15 | $7.30 | +105.48% | 6 | Sep 17, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underweight | $13 | $18.12 | -28.26% | 1 | Sep 17, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | $45 | $32.34 | +39.15% | 5 | Sep 17, 2025 | |
| PTGX Protagonist Therapeutics | Initiates: Overweight | $72 | $58.59 | +22.89% | 3 | Sep 17, 2025 | |
| MRUS Merus | Initiates: Overweight | $112 | $66.90 | +67.41% | 7 | Sep 17, 2025 | |
| JANX Janux Therapeutics | Initiates: Overweight | $47 | $23.41 | +100.77% | 1 | Sep 17, 2025 | |
| CCCC C4 Therapeutics | Initiates: Overweight | $8 | $3.41 | +134.60% | 4 | Sep 17, 2025 | |
| IVA Inventiva | Maintains: Buy | $9 → $13 | $5.32 | +144.36% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $82 → $20 | $7.64 | +161.78% | 4 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $143 | $99.26 | +44.07% | 4 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $1.88 | +59.57% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $47.71 | +4.80% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $8.44 | +314.69% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $55 | $48.78 | +12.75% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $2.43 | +2,492.59% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.55 | +1,641.94% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $78.33 | +71.07% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 → $34 | $8.62 | +294.43% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $28.24 | +69.97% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $122.78 | -2.26% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $25 | $8.61 | +190.36% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $5 | $1.47 | +240.14% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $0.95 | +531.11% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $77.56 | +5.72% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $4.90 | +287.76% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $461.24 | -63.14% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $42.60 | +26.76% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $73.79 | -48.50% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $1.84 | +2,726.09% | 1 | Mar 28, 2018 |
Exelixis
Sep 17, 2025
Initiates: Equal-Weight
Price Target: $40
Current: $39.14
Upside: +2.20%
CytomX Therapeutics
Sep 17, 2025
Assumes: Overweight
Price Target: $3.5
Current: $1.96
Upside: +78.57%
Terns Pharmaceuticals
Sep 17, 2025
Initiates: Overweight
Price Target: $15
Current: $7.30
Upside: +105.48%
Summit Therapeutics
Sep 17, 2025
Initiates: Underweight
Price Target: $13
Current: $18.12
Upside: -28.26%
Scholar Rock Holding
Sep 17, 2025
Initiates: Overweight
Price Target: $45
Current: $32.34
Upside: +39.15%
Protagonist Therapeutics
Sep 17, 2025
Initiates: Overweight
Price Target: $72
Current: $58.59
Upside: +22.89%
Merus
Sep 17, 2025
Initiates: Overweight
Price Target: $112
Current: $66.90
Upside: +67.41%
Janux Therapeutics
Sep 17, 2025
Initiates: Overweight
Price Target: $47
Current: $23.41
Upside: +100.77%
C4 Therapeutics
Sep 17, 2025
Initiates: Overweight
Price Target: $8
Current: $3.41
Upside: +134.60%
Inventiva
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $5.32
Upside: +144.36%
Mar 12, 2025
Maintains: Outperform
Price Target: $82 → $20
Current: $7.64
Upside: +161.78%
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $99.26
Upside: +44.07%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $1.88
Upside: +59.57%
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $47.71
Upside: +4.80%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $8.44
Upside: +314.69%
Dec 6, 2024
Initiates: Market Perform
Price Target: $55
Current: $48.78
Upside: +12.75%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $2.43
Upside: +2,492.59%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.55
Upside: +1,641.94%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $78.33
Upside: +71.07%
Nov 8, 2024
Reiterates: Outperform
Price Target: $32 → $34
Current: $8.62
Upside: +294.43%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $28.24
Upside: +69.97%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $122.78
Upside: -2.26%
Aug 13, 2024
Maintains: Outperform
Price Target: $26 → $25
Current: $8.61
Upside: +190.36%
Aug 7, 2024
Maintains: Market Perform
Price Target: $8 → $5
Current: $1.47
Upside: +240.14%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $0.95
Upside: +531.11%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $77.56
Upside: +5.72%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $4.90
Upside: +287.76%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $461.24
Upside: -63.14%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $42.60
Upside: +26.76%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $73.79
Upside: -48.50%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $1.84
Upside: +2,726.09%